Fidaxomicin -- Benefit Assessment According to §35a Social Code Book V [Internet].

The aim of this report is to assess the added benefit of fidaxomicin according to its approval for the following therapeutic indication: treatment of Clostridium difficile infections (CDI) also known as Clostridium difficile-associated diarrhoea (CDAD).

http://ift.tt/2ruBHkm